Leiden University Medical Center, Department of Surgery, Albinusdreef 2, Postbus 9600, 2300, RC Leiden, the Netherlands.
Netherlands Comprehensive Cancer Organization, Department of Research and Development, Godebaldkwartier 419, Postbus 19079, 3501, DB Utrecht, the Netherlands.
Eur J Surg Oncol. 2021 Jul;47(7):1651-1660. doi: 10.1016/j.ejso.2021.01.011. Epub 2021 Jan 21.
Mortality in the first postoperative year represents an accurate reflection of the perioperative risk after colorectal cancer surgery. This research compares one-year mortality after surgery divided into three age-categories (18-64, 65-74, ≥75 years), focusing on time trends and comparing treatment strategies.
Population-based data of all patients diagnosed and treated surgically for stage I-III primary colorectal cancer from 2007 to 2016, were collected from Belgium, the Netherlands, Norway, and Sweden. Stratified for age-category and stage, treatment was evaluated, and 30-day, one-year and one-year excess mortality were calculated for colon and rectal cancer separately. Results were evaluated over two-year time periods.
Data of 206,024 patients were analysed. Postoperative 30-day and one-year mortality reduced significantly over time in all countries and age-categories. Within the oldest age category, in 2015-2016, one-year excess mortality varied from 9% in Belgium to 4% in Sweden for colon cancer and, from 9% in Belgium to 3% in the other countries for rectal cancer. With increasing age, patients were less likely to receive additional therapy besides surgery. In Belgium, colon cancer patients were more often treated with adjuvant chemotherapy (p < 0.001). For neoadjuvant treatment of rectal cancer, patients in Belgium and Norway were mostly treated with chemoradiotherapy. In the Netherlands and Sweden, radiotherapy alone was preferred (p < 0.001).
Despite improvement over time in all countries and age-categories, substantial variation exists in one-year postoperative mortality. Differences in one-year excess postoperative mortality could be due to differences in treatment strategies, highlighting the consequences of under- and over-treatment on cancer survival.
结直肠癌手术后的第 1 年的死亡率是围手术期风险的准确反映。本研究比较了手术分为三个年龄组(18-64 岁、65-74 岁、≥75 岁)后的 1 年死亡率,重点关注时间趋势并比较治疗策略。
从比利时、荷兰、挪威和瑞典收集了 2007 年至 2016 年间所有 I-III 期原发性结直肠癌患者的基于人群的诊断和手术治疗数据。按年龄组和分期分层,评估治疗方法,并分别计算结肠癌和直肠癌的 30 天、1 年和 1 年超额死亡率。结果在两年时间段内进行评估。
共分析了 206024 名患者的数据。所有国家和年龄组的术后 30 天和 1 年死亡率均随时间显著降低。在最年长的年龄组中,2015-2016 年,比利时结肠癌 1 年超额死亡率为 9%,瑞典为 4%,而其他国家为 9%,直肠癌症为 3%。随着年龄的增长,患者除手术外接受额外治疗的可能性降低。在比利时,更多的结肠癌患者接受辅助化疗(p<0.001)。对于新辅助治疗直肠癌,比利时和挪威的患者大多接受放化疗。荷兰和瑞典则更喜欢单独放疗(p<0.001)。
尽管所有国家和年龄组的死亡率随时间有所改善,但 1 年后的死亡率仍存在显著差异。术后 1 年超额死亡率的差异可能是由于治疗策略的差异造成的,这突出了治疗不足和过度对癌症生存的影响。